*Eligible patients without diabetes lost an average of 21% of their body weight (-48 lbs) in a 72-week clinical trial evaluating 15 mg tirzepatide, when paired with diet and exercise
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, and Bloom SR
Frequently asked questions Can I use the same retatrutide vial for different dose levels during titration
2 Material and methods This narrative literature review examines the use of SGLT-2 inhibitors and GLP-1 RAs in patients with T2DM and CVD
Current Legal Status in the UK As of now, Retatrutide is not an approved medication in the UK and remains in Phase 3 trials
10.1038/nn.4540 69 TurtonM